Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.67
OMER's Cash to Debt is ranked lower than
73% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. OMER: 1.67 )
Ranked among companies with meaningful Cash to Debt only.
OMER' s 10-Year Cash to Debt Range
Min: 0.21  Med: 1.62 Max: N/A
Current: 1.67
Equity to Asset 0.14
OMER's Equity to Asset is ranked lower than
89% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OMER: 0.14 )
Ranked among companies with meaningful Equity to Asset only.
OMER' s 10-Year Equity to Asset Range
Min: -15.24  Med: -0.23 Max: 0.7
Current: 0.14
-15.24
0.7
F-Score: 4
Z-Score: -2.44
M-Score: 3.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1788.96
OMER's Operating margin (%) is ranked lower than
82% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. OMER: -1788.96 )
Ranked among companies with meaningful Operating margin (%) only.
OMER' s 10-Year Operating margin (%) Range
Min: -12988.5  Med: -1433.87 Max: -605.88
Current: -1788.96
-12988.5
-605.88
Net-margin (%) -1874.25
OMER's Net-margin (%) is ranked lower than
83% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. OMER: -1874.25 )
Ranked among companies with meaningful Net-margin (%) only.
OMER' s 10-Year Net-margin (%) Range
Min: -13668.46  Med: -1425.03 Max: -630.99
Current: -1874.25
-13668.46
-630.99
ROA (%) -176.34
OMER's ROA (%) is ranked lower than
91% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. OMER: -176.34 )
Ranked among companies with meaningful ROA (%) only.
OMER' s 10-Year ROA (%) Range
Min: -533.38  Med: -97.57 Max: -50.37
Current: -176.34
-533.38
-50.37
ROC (Joel Greenblatt) (%) -8718.34
OMER's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. OMER: -8718.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OMER' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8158.4  Med: -3788.46 Max: -2046.97
Current: -8718.34
-8158.4
-2046.97
Revenue Growth (3Y)(%) -53.60
OMER's Revenue Growth (3Y)(%) is ranked lower than
83% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. OMER: -53.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OMER' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -21.30 Max: 7.7
Current: -53.6
0
7.7
EBITDA Growth (3Y)(%) 21.20
OMER's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. OMER: 21.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OMER' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -18.70 Max: 21.2
Current: 21.2
0
21.2
EPS Growth (3Y)(%) 19.80
OMER's EPS Growth (3Y)(%) is ranked higher than
77% of the 420 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. OMER: 19.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OMER' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -18.30 Max: 19.8
Current: 19.8
0
19.8
» OMER's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

OMER Guru Trades in Q4 2013

Paul Tudor Jones 10,807 sh (New)
» More
Q1 2014

OMER Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
» More
Q1 2015

OMER Guru Trades in Q1 2015

Jim Simons 64,435 sh (New)
» More
Q2 2015

OMER Guru Trades in Q2 2015

Jim Simons 136,307 sh (+111.54%)
» More
» Details

Insider Trades

Latest Guru Trades with OMER

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 714.29
OMER's Forward P/E is ranked lower than
97% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 22.73 vs. OMER: 714.29 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 74.81
OMER's P/B is ranked lower than
99% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. OMER: 74.81 )
Ranked among companies with meaningful P/B only.
OMER' s 10-Year P/B Range
Min: 2.76  Med: 8.29 Max: 100.29
Current: 74.81
2.76
100.29
P/S 141.40
OMER's P/S is ranked lower than
91% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. OMER: 141.40 )
Ranked among companies with meaningful P/S only.
OMER' s 10-Year P/S Range
Min: 15.16  Med: 43.33 Max: 1250.5
Current: 141.4
15.16
1250.5
Current Ratio 2.82
OMER's Current Ratio is ranked lower than
63% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. OMER: 2.82 )
Ranked among companies with meaningful Current Ratio only.
OMER' s 10-Year Current Ratio Range
Min: 0.41  Med: 2.05 Max: 6.61
Current: 2.82
0.41
6.61
Quick Ratio 2.79
OMER's Quick Ratio is ranked lower than
61% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. OMER: 2.79 )
Ranked among companies with meaningful Quick Ratio only.
OMER' s 10-Year Quick Ratio Range
Min: 0.41  Med: 2.05 Max: 6.61
Current: 2.79
0.41
6.61
Days Inventory 343.06
OMER's Days Inventory is ranked lower than
89% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: 120.98 vs. OMER: 343.06 )
Ranked among companies with meaningful Days Inventory only.
OMER' s 10-Year Days Inventory Range
Min: 0  Med: 0.00 Max: 0
Current: 343.06
Days Sales Outstanding 282.42
OMER's Days Sales Outstanding is ranked lower than
92% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. OMER: 282.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMER' s 10-Year Days Sales Outstanding Range
Min: 36.06  Med: 78.57 Max: 265.45
Current: 282.42
36.06
265.45

Valuation & Return

vs
industry
vs
history
Price/Net Cash 788.00
OMER's Price/Net Cash is ranked lower than
100% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 7.71 vs. OMER: 788.00 )
Ranked among companies with meaningful Price/Net Cash only.
OMER' s 10-Year Price/Net Cash Range
Min: 3.62  Med: 15.26 Max: 899.5
Current: 788
3.62
899.5
Price/Net Current Asset Value 98.50
OMER's Price/Net Current Asset Value is ranked lower than
98% of the 537 Companies
in the Global Biotechnology industry.

( Industry Median: 6.85 vs. OMER: 98.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OMER' s 10-Year Price/Net Current Asset Value Range
Min: 3.58  Med: 10.56 Max: 112.44
Current: 98.5
3.58
112.44
Price/Tangible Book 75.05
OMER's Price/Tangible Book is ranked lower than
98% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. OMER: 75.05 )
Ranked among companies with meaningful Price/Tangible Book only.
OMER' s 10-Year Price/Tangible Book Range
Min: 3.46  Med: 9.16 Max: 85.67
Current: 75.05
3.46
85.67
Price/Median PS Value 3.30
OMER's Price/Median PS Value is ranked lower than
92% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. OMER: 3.30 )
Ranked among companies with meaningful Price/Median PS Value only.
OMER' s 10-Year Price/Median PS Value Range
Min: 0.43  Med: 1.09 Max: 28.48
Current: 3.3
0.43
28.48
Earnings Yield (Greenblatt) (%) -12.28
OMER's Earnings Yield (Greenblatt) (%) is ranked lower than
57% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. OMER: -12.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OMER' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -15.66  Med: 0.00 Max: 0
Current: -12.28
-15.66
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 26 115 239
EPS($) -1.85 0.02 2.04
EPS without NRI($) -1.85 0.02 2.04

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:3O8.Germany,
Omeros Corp is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system. Its product OMS302 or Omidria completed its Phase 3 clinical trial is used for lens replacement surgery and is derived from its PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. In November 2013, the FDA conditionally accepted Omidria as the proposed brand name for OMS302 in the U.S. and in December 2013, the EMA accepted Omidria as the proposed brand name for OMS302 in the EU. In addition to Omidria, the Company has other development programs for pain, inflammation, coagulopathies and disorders of the central nervous system. It has six clinical-stage programs in its pipeline; OMS103 for inflammatory pain following arthroscopic partial meniscectomy surgery, which has completed one Phase 3 trial, its PDE10 inhibitor OMS824 for schizophrenia, which is in a Phase 2 clinical program for patients with stable schizophrenia, its PDE10 inhibitor OMS824 for Huntington's disease, which is in Phase 2 clinical program, its MASP-2 antibody OMS721 for the treatment of thrombotic microangiopathies, which has completed dosing in Phase 1 clinical trial and a Phase 2 clinical program is underway, its PPAR? program, in which three Phase 2 clinical trials are being conducted by its collaborators to evaluate a PPAR? agonist, alone or in combination with other agents, for treatment of addiction to opioids and to nicotine and its PharmacoSurgery product OMS201 for use during urological procedures, including uroendoscopic procedures, that has completed a Phase 1/Phase 2 clinical trial in 2010 and is not currently in active clinical trials. As of February 15, 2014, the Company owned or held licenses to a total of 51 issued or allowed patents and 51 pending patent applications in the U.S. and 245 issued or allowed patents and 230 pending patent applications in foreign markets. The Company is subject to regulate under the U.S. and EU governing regulations.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK